Clinical Trial

Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China

Study acronym: ECHO
Recruiting
View on ClinicalTrials.gov →
Summary
This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.
Protocol Amendment History 2 changes
notable Trial sites expanded: 1 -> 14 locations 2026-08-14
critical Recruitment opened 2026-07-10
Trial Details
NCT Number NCT07593248
Lead Sponsor AstraZeneca
Conditions Lung Cancer
Enrollment 2,000 participants
Start Date 2026-06-22
Primary Completion 2031-06-30 (estimated)
Study Completion 2031-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-13